seribantumab

Seribantumab is a human monoclonal antibody that targets ErbB3, also known as HER3. ErbB3 is a receptor tyrosine kinase that plays a role in cell growth and survival, and it is often overexpressed or activated in various types of cancer. Seribantumab works by binding to ErbB3 and blocking its interaction with other ErbB family members, particularly ErbB2 (HER2) and neuregulin. This blockade is thought to inhibit downstream signaling pathways that promote tumor proliferation and survival.

The development of seribantumab has focused on its potential as a therapeutic agent for solid tumors. Clinical trials have investigated its efficacy in combination with other anti-cancer drugs, such as chemotherapy agents or other targeted therapies. These trials have aimed to assess its safety and effectiveness in patients with specific types of cancer, including non-small cell lung cancer and gastric cancer. Research is ongoing to further understand the optimal use of seribantumab, including identifying biomarkers that can predict patient response to treatment and exploring its potential in different cancer indications.